Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.7952W HIGH $41.72
Volume
7.70 K
Value Traded
229.34 K
Short % Float
0.45%
-2.12%Week
+26.14%1 Month
+45.31%3 Month
-13.61%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
136.53 M
EPS (TTM)
-0.72
P/E Ratio
-
Ent. Value
107.92 M
Total Shares
8.81 M
Float Shares
8.76 M
Insiders
0.24%
Institutions
19.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BNR Catalyst Timeline
Dated clinical, regulatory and corporate events for Burning Rock Biotech Limited American Depositary Shares
Past FDA Catalysts and PDUFA Decisions
How BNR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Burning Rock Biotech Limited is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BNR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Han YushengDirector | Buy | 24,900 18,404,086 held | $8.00 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BNR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 0.6 % (-50 %) | 10.52 M | 1.24 M | 0.9% ( 11.01 K) |
BNR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BNR ranks across every disease it competes in
Competitive Position is a premium feature
See how BNR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBNR News
-BNR
Jun 9, 2026▼ -9.8%on this news
Burning Rock Reports First Quarter 2026 Financial Results
Burning Rock Biotech Limited reported its financial results for Q1 2026, showing an 18.9% decrease in revenue compared to the same period in 2025. The company highlighted promising study results at the AACR 2026, but faced challenges with declining revenues in its central laboratory and pharma research services. Despite a slight improvement in gross margins for certain segments, the overall net loss increased.
Read more →-BNR
Mar 12, 2026Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results
Burning Rock Biotech Limited reported its unaudited financial results for the fourth quarter and full year of 2025. Revenue for Q4 2025 was RMB 126.3 million, stable compared to the previous year, while gross profit saw a significant increase. Operating expenses were reduced notably due to cost control measures. Overall, while the company continued to report a net loss, the losses were considerably smaller than in the previous year, indicating improvements in operational efficiency.
Read more →-BNR
Jan 5, 2026▲ +24.4%on this news
Burning Rock Announces Founder’s Purchase of Its ADSs
Burning Rock Biotech Limited announced that its founder and CEO, Mr. Yusheng Han, has purchased over $811,000 worth of the company's American Depositary Shares (ADSs) from the open market. This purchase is seen as a sign of confidence in the company's business prospects. Mr. Han may continue to acquire more ADSs depending on market conditions and regulatory compliance.
Read more →-BNR
Dec 23, 2025▼ -6.9%on this news
Burning Rock Announces Results of 2025 Annual General Meeting
Burning Rock Biotech Limited announced the successful passing of all shareholder resolutions at its 2025 annual general meeting. This indicates strong support from shareholders for the company's strategies and goals. The company is focused on next generation sequencing technology in precision oncology and has made significant progress in cancer early detection advancements. This meeting reflects the commitment of the company to its mission of utilizing science to enhance life.
Read more →-BNR
Dec 1, 2025▼ -12%on this news
Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025
Burning Rock Biotech Limited has announced its Annual General Meeting (AGM) will take place on December 23, 2025, at its Shanghai office. The board of directors supports the proposals to be voted on during the meeting. Shareholders must be recorded by December 1, 2025, to participate. The company has also filed its annual report with the SEC.
Read more →-BNR
Nov 20, 2025Burning Rock Reports Third Quarter 2025 Financial Results
Burning Rock Biotech Limited reported its financial results for Q3 2025, indicating total revenues of RMB131.6 million, a 2.3% increase over the previous year. Operating expenses decreased by 11.9%, resulting in a gross profit increase of 7.6% to RMB98.8 million. Despite the net loss of RMB16.8 million, which is lower than last year, the company continues to focus on precision oncology with its next-generation sequencing technology.
Read more →-BNR
Sep 8, 2025▲ +9.2%on this news
Burning Rock Reports Second Quarter 2025 Financial Results
Burning Rock Biotech Limited has reported its financial results for the second quarter of 2025, showing a revenue increase of 9.6% year-over-year to RMB148.5 million. Gross profit also rose by 13.3%, leading to a gross margin of 72.8%. Significant operating cost-cutting measures led to a 42.1% fall in operating expenses from the previous year. However, the company reported a net loss of RMB9.7 million in the quarter, leading to a mixed outlook despite positive revenue growth.
Read more →-BNR
Jun 6, 2025Burning Rock Reports First Quarter 2025 Financial Results
Burning Rock Biotech Limited (NASDAQ: BNR) reported its financial results for Q1 2025, showing positive growth in revenues and gross profit. The company's revenues reached RMB133.1 million, marking a 5.9% increase from the previous year. Gross profit improved by 13.7%, while gross margins also rose to 73.2%. Operating expenses saw a significant decrease due to cost-control measures, which contributed to enhanced operational efficiency.
Read more →-BNR
Mar 25, 2025▼ -12.4%on this news
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results GUANGZHOU, China, March 25, 2025 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused
Burning Rock Biotech Limited reported its unaudited financial results for the fourth quarter and full year of 2024. The company experienced a 4.1% increase in revenue for Q4 compared to the same period in 2023, alongside a 14.5% rise in gross profit. However, total revenue for the full year declined by 4.0% from the previous year. The company successfully reduced operating expenses significantly, reflecting a focused effort on cost management despite a continued net loss.
Read more →-BNR
Dec 31, 2024Burning Rock Announces Results of 2024 Annual General Meeting
Burning Rock Biotech Limited has announced the results from its 2024 annual general meeting, where all proposed shareholder resolutions were successfully passed. The company continues to focus on innovative applications of next generation sequencing technology, specifically within precision oncology. Its advancements have moved from proof-of-concept research and development to the clinical validation stage, suggesting a positive trajectory for its NGS-based therapy and early cancer detection services.
Read more →-BNR
Dec 4, 2024▲ +13.7%on this news
Burning Rock Reports Third Quarter 2024 Financial Results
Burning Rock Biotech Limited reported its financial results for Q3 2024, highlighting a slight revenue increase to RMB128.6 million. The company saw a significant improvement in gross margin and reduced operating expenses by over 50% compared to the previous year. However, the business is experiencing a shift from central-lab to in-hospital testing, which impacted revenues in its central laboratory segment. Despite a net loss of RMB35.7 million, this figure marks a notable improvement from the same period in 2023.
Read more →-BNR
Dec 3, 2024Burning Rock Announces 2024 Annual General Meeting to be Held on
Burning Rock Biotech Limited has announced its Annual General Meeting (AGM) scheduled for December 31, 2024, in Shanghai. Shareholders of the company's Class A and Class B ordinary shares will be able to attend and vote on proposed resolutions. The company has also filed its annual report for the year ended December 31, 2023, with the SEC, which is accessible online. The AGM reflects the company's commitment to transparency and shareholder engagement.
Read more →-BNR
Sep 27, 2024Burning Rock Announces Changes to Management and Board of Directors
Burning Rock Biotech Limited announced changes in its management and board of directors, including the resignation of Mr. Leo Li. His departure, effective September 27, 2024, was for personal reasons and not due to any disagreements. Ms. Xiaozhi Hu will now oversee financial operations, having been with the company since 2014. The company's chairman acknowledged Mr. Li's contributions to key developments, including the initial public offering.
Read more →-BNR
Aug 23, 2024▼ -6.8%on this news
Burning Rock Reports Second Quarter 2024 Financial Results
Burning Rock Biotech Limited reported its financial results for the second quarter of 2024, indicating a decrease in total revenue to RMB135.5 million, down 7.3% from the previous year. Despite this, the in-hospital segment continued to exhibit robust double-digit growth. The company's gross margin improved to 70.4%, and operating expenses were notably reduced by 12.5%, reflecting effective budget management. However, the net loss widened compared to the same period last year, signaling ongoing challenges in achieving profitability.
Read more →-BNR
Jun 3, 2024Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
Burning Rock Biotech Limited has announced that it has regained compliance with NASDAQ's minimum bid price requirement after receiving notification on May 30, 2024. The company had previously struggled with share prices falling below the required $1.00 for 30 consecutive business days. To address this issue, Burning Rock adjusted the ratio of its American depositary shares, which became effective on May 15, 2024. Following this change, the company's shares have remained above the minimum bid price for the required duration, allowing it to close the compliance matter with NASDAQ.
Read more →-BNR
May 29, 2024Burning Rock Reports First Quarter 2024 Financial Results
Burning Rock Biotech Limited reported its financial results for the first quarter of 2024, showing an 11.9% decrease in total revenues compared to the previous year. While the in-hospital testing segment continued to grow, overall revenues were negatively impacted by a shift away from central lab operations. The company saw a reduction in operating expenses and maintained a substantial cash reserve. Despite a reduced net loss, challenges remain in achieving positive growth in various segments.
Read more →-BNR
May 15, 2024Burning Rock Announces ADS Ratio Change to Be Effective on
Burning Rock Biotech Limited announced a change in its American depositary shares (ADS) ratio, effective May 15, 2024. The new ratio will be one ADS representing ten Class A ordinary shares, resulting in a reverse ADS split. While the ADS price is expected to increase proportionally, the company cannot guarantee that it will reach or exceed ten times the previous price. This change is designed to streamline trading for existing shareholders.
Read more →-BNR
Apr 26, 2024Burning Rock Announces ADS Ratio Change
Burning Rock Biotech Limited announced a modification in its American depositary shares (ADS) ratio, transitioning from one ADS for one Class A ordinary share to one ADS for ten shares. This change, set to take effect around May 15, 2024, is likened to a one-for-ten reverse split. While the company anticipates a proportional increase in ADS prices, it does not guarantee that the post-change price will be at least ten times the previous price. The company continues to focus on next generation sequencing technology in precision oncology, with ongoing efforts in therapy selection testing and cancer detection.
Read more →-BNR
Mar 29, 2024Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
Burning Rock Biotech Limited reported its financial results for the fourth quarter and full year of 2023, highlighting a decline in revenues and gross profits compared to previous periods. Specifically, fourth quarter revenues fell by 14.9% year-over-year, while the full year revealed a 4.6% revenue decrease. Despite cost-cutting measures that led to a reduction in operating expenses, the company still faced a net loss of RMB653.7 million for 2023. Management expects to reach breakeven in the first half of 2024, but the latest results indicate ongoing financial struggles.
Read more →-BNR
Jan 4, 2024Burning Rock Announces Receipt of Notification from
Burning Rock Biotech Limited has received notification from NASDAQ indicating that its American depositary shares (ADSs) closed below the minimum bid price of $1.00 for 30 consecutive business days. The company is granted a compliance period of 180 days to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days. Alternatively, if it fails to comply by the deadline, the company may qualify for an additional 180 days. The notification does not affect the company's business operations or trading of its securities.
Read more →About Burning Rock Biotech Limited American Depositary Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next BNR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime